期刊文献+

高危型人乳头瘤病毒阴性/不典型鳞状细胞和低度鳞状上皮内病变患者的随访观察 被引量:16

An analysis of high-risk human papillomavirus DNA-negative cervical intraepithelial neoplasia in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion smears: a retrospective study
下载PDF
导出
摘要 目的:分析高危型人乳头瘤病毒( high-risk human papillomavirus,HR-HPV)阴性的不典型鳞状细胞( atypical squamous cells undetermined significance,ASCUS)和低度鳞状上皮内病变( low squamous intraepithelial lesion,LSIL)患者的随访结果,探讨HR-HPV阴性的ASCUS和LSIL患者的合理处理方法。方法回顾性分析2010年1月1日至2012年12月31日期间,就诊于首都医科大学附属北京朝阳医院妇科门诊,HR-HPV阴性、宫颈液基细胞学为ASCUS和LSIL的356例患者的病理资料,对HR-HPV阴性的ASCUS和LSIL经阴道镜及宫颈活检排除高级别病变的306例患者定期进行HR-HPV随访。 HR-HPV检测采用杂交检测法2代(hybird capture-Ⅱ,HC-Ⅱ)。结果 HR-HPV阴性/ASCUS和LSIL患者宫颈上皮内瘤变(cervical intraepithelial lesions,CIN)-Ⅲ及以上病变发病率分别为7.9%和9.1%。 HR-HPV阳性/ASCUS和LSIL患者CIN -Ⅲ及以上病变发病率分别是22.9%和17.9%。 HR-HPV阳性的ASCUS和LSIL患者CIN-Ⅲ及以上病变发病率明显高于HR-HPV阴性患者,差异具有统计学意义(P=0.000)。 HR-HPV阳性对ASCUS及LSIL患者宫颈高级别病变的阴性预测值分别为87.13%和84.42%。 HR-HPV阴性/ASCUS和LSIL患者CIN-Ⅱ及以上病变检出率是14.3%。不同年龄段的HR-HPV阴性/ASCUS和LSIL的患者,宫颈高级别病变患者的发生率不同,差异具有统计学意义(P〈0.05)。30~39岁妇女宫颈高级别病变的发生率最高(18.2%)。结论 HR-HPV阴性的ASCUS和LSIL患者发生CIN-Ⅲ及以上病变分别是7.9%和9.1%,CIN-Ⅱ及以上病变达14.3%,30~39岁的HR-HPV阴性/ASCUS和LSIL患者宫颈高级别病变发生率达18%,建议对于HR-HPV阴性的ASCUS和LSIL患者应行阴道镜检查可疑病变部位活检。 Objective To evaluate the cervical pathology among high-risk human papillomavirus ( HR-HPV )-negative women with atypical squamous cells of undetermined significance ( ASCUS ) cells and low-grade squamous intraepithelial lesion ( LSIL ) , and to investigate the reasonable management strategies for HR-HPV-negative patients with ASCUS and LSIL. Methods In this retrospective study, 356 cases who visited the Department of Gynecology, Beijing Chaoyang Hospital Affiliated to Capital Medical University during January 1, 2010 to 31 December 2012, and were HR-HPV-negative/ASCUS and LSIL on Pap smear were included;306 patients were followed up. All the patients were examined by colposcopy and cervical biopsy if necessary. HR-HPV was detected by hybridization assay II, hybird capture Ⅱ(HC-Ⅱ). SPSS18. 0 statistical software was used. Results Of the 202 cases, 16(7. 9%) and 14 of 154(9. 1%) HR-HPV negative ASCUS and LSIL women developed CIN-Ⅲor worse compared with 32 of 140(22. 9%) and 40 of 223(17. 9%) HPV-positive ASCUS and LSIL women(P=0. 000). The negative predictive value of HR-HPV testing for CIN-Ⅲor worse in ASCUS and LSIL women were 87. 13% and 84. 42%, respectively. When cervical pathological data were further evaluated by age groups in HR-HPV-negative women with ASCUS and LSIL, the risk of ≧CIN-Ⅱ were significantly different in various age groups(P〈0. 05) , the highest group was 30-39 years old patients(18. 2%) . Conclusion HR-HPV-negative patients with an ASCUS or LSIL Pap test result have a chance of being cervical high grade lesions, 7. 9% and 9. 1% of HR-HPV-negative patients with ASCUS or LSIL had CIN-Ⅲ or worse, and 14. 3% of these patients had CIN -Ⅱ or worse lesions, the negative predictive value of HR-HPV testing for CIN -Ⅲ or worse were lower. Colposcopy should be done for HR-HPV-negative patients with ASCUS or LSIL.
出处 《首都医科大学学报》 CAS 北大核心 2015年第2期205-211,共7页 Journal of Capital Medical University
基金 北京市自然科学基金(7122069) 北京市科学技术委员会科技计划(Z131100004013018) 北京市金桥工程种子资金项目(2014-2016)~~
关键词 高危型人乳头瘤病毒 不典型鳞状细胞 低度鳞状上皮内病变 宫颈上皮内瘤变 high-risk human papillomavirus( HR-HPV) atypical squamous cells of undetermined significance( ASCUS) low-grade squamous intraepithelial lesion( LSIL) cervical intraepithelial neoplasia( CIN)
  • 相关文献

参考文献14

  • 1Arbyn M , Castellsague X, de Sanjose S, et al. Worldwide burden of cervicalcancer in 2008 [ J ]. Ann Oneol, 2011,22 (12) :2675- 2686.
  • 2曹泽毅.中华妇产科学[J].2版.北京:人民卫生出版社,2004:1848—1852,2012—2028.
  • 3Martin J L, Baxter R C. Signalling pathways of insulin like growthfactors (IGFs) and IGF binding protein 3 [ J ]. Growth Factors, 2011,29(6) :235-244.
  • 4Mdnikow J, Nuovo J, Willan A R, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis [ J]. Obstet Gynecol, 1998,92:727-735.
  • 5Gage J C, Katki H A, Schiffman M, et al. The low risk of precancer after a screening result of human papillomavirus- negative/atypical squamous cells of undetermined signifi-cance papanicolaou and implications for clinical manage- ment [ J ]. Cancer Cytopathol, 2014,122 ( 11 ) :842-850.
  • 6Arbyn M, Sasieni P, Meijer C J, et al. Clinical applica- tions of HPV testing: a su mmary of meta-analyses [ J ]. Vaccine, 2006, 24( Suppl 3) :78-89.
  • 7Li C D, Wu M H, Wang J D, et al. A population based study on the risks of cervical lesion and human papilloma- virus infection among women in Beijing, people's Republic of China [ J ]. Cancer Epidem Biomarm, 2010, 19 ( 10 ) : 2656- 2664.
  • 8Trop A, Sjcborg K D, Nyg hrd M, et al. Cytology and hu- man papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds [ J ]. J Clin Mi- crobiol, 2012,50(6) : 1927- 1935.
  • 9Castle P E, Cox J T, Jeronimo J, et al. An analysis of high-risk human papillomavirus DNA-negative cervical pre- cancers in the ASCUS-LSIL Triage Study (ALTS) [ J ]. Ob- stet Gynecol, 2008,111 (4) : 847-856.
  • 10Coupe V M, Berkhof J, Bulkmans N W, et al. Age-de-pendent prevalence of 14 high-risk HPV types in the Neth- erlands: implications for prophylactic vaccination and screening[J]. Br J Cancer, 2008,98(3) :646-651.

二级参考文献12

共引文献80

同被引文献155

  • 1刘艳波,李玉娟,张坚,谢静燕.TCT和DNA倍体分析在子宫良性疾病术前检查中的临床价值[J].实用医技杂志,2008,15(32):4533-4535. 被引量:3
  • 2谢幸,苟文丽.妇产科学[M].8版.北京:人民卫生出版社,2013:118-119.
  • 3Saslow D,Solomon D,Lawson H W,et al. AmericanCancer Society, American Society for Colposcopy andCervical Pathology,and American Society for Clinical Pa-thology screening guidelines for the prevention and earlydetection of cervical cancer[J]. Am J Clin Pathol,2012,137( 4) : 516-542.
  • 4Won K H,Lee J Y,Cho H Y,et al. Impact of age onthe false negative rate of human papillomavirus DNA testin patients with atypical squamous cells of undeterminedsignificance[J]. Obstet Gynecol Sci,2015,58 ( 2 ) : 117-123.
  • 5Solomon D,Davey D,Kurman R,et al. The 2001 Be-thesda System: terminology for reporting results of cervicalcytology[J]. JAMA,2002,287( 16) : 2114-2119.
  • 6Rubio C A,Auer G U,Kato Y,et al. DNA profiles indysplasia and carcinoma of the human esophagus[J].Anal Quant Cytol Histol,1988,10( 3) : 207-210.
  • 7Massad L S,Einstein M H,Huh W K,et al. 2012 up-dated consensus guidelines for the management of abnor-mal cervical cancer screening tests and cancer precursors[J]. Obstet Gynecol,2013,121( 4) : 829-846.
  • 8Safaeian M,Solomon D,Wacholder S,et al. Risk ofprecancer and follow-up management strategies for womenwith human papillomavirus-negative atypical squamouscells of undetermined significance[J]. Obstet Gynecol,2007,109( 6) : 1325-1331.
  • 9Zhao C,Zhao S,Heider A,et al. Significance of high-risk human papillomavirus DNA detection in women 50years and older with squamous cell papanicolaou test ab-normalities[J]. Arch Pathol Lab Med,2010,134 ( 8 ) :1130-1135.
  • 10Bollmann R,Mehes G,Torka R,et al. Determination offeatures indicating progression in atypical squamous cellswith undetermined significance: human papillomavirustyping and DNA ploidy analysis from liquid-based cyto-logic samples[J]. Cancer,2003,99( 2) : 113-117.

引证文献16

二级引证文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部